Ruxolitinib Cream for Seborrheic Dermatitis

Recruiting in Palo Alto (17 mi)

Overseen byBenjamin Ungar, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Icahn School of Medicine at Mount Sinai

No Placebo Group

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.

Research Team

Benjamin Ungar, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Adults with seborrheic dermatitis (SD) who haven't responded to standard treatments like antifungals or low-potency steroids can join. They must have a moderate SD severity, not use other SD treatments during the trial, and be in good health. Women of childbearing age need a negative pregnancy test and agree to use contraception.

Inclusion Criteria

I am not pregnant, will use effective birth control during the study, and for 90 days after.

I have tried at least one treatment for my condition without success.

My skin condition is moderate to severe and affects my face.

See 5 more

Exclusion Criteria

I do not have any major health issues that could affect my participation in the study.

Subject who is pregnant or breast feeding

I have not had a skin infection in the last 2 weeks.

See 8 more

Treatment Details

Interventions

Ruxolitinib (Janus Kinase (JAK) Inhibitor)

Trial OverviewThe trial is testing Ruxolitinib cream's effectiveness on seborrheic dermatitis by comparing immune responses before and after treatment over four weeks. It's an open-label study, meaning everyone knows they're getting the actual drug without any placebos involved.

Participant Groups

2Treatment groups

Active Control

Group I: Healthy Control SubjectsActive Control1 Intervention

Age- and gender-matched healthy control subjects

Group II: Ruxolitinib CreamActive Control1 Intervention

Participants will receive topical ruxolitinib 1.5% cream